Abbott posted strong organic growth of 11% in Q4 when excluding Covid testing sales. This year the stock will hit a milestone: 400 consecutive quarterly dividend payments. But consistency doesn't come ...

The S&P 500 has performed well in 2023, but healthcare stocks have lagged behind. Abbott Laboratories continues to lap difficult comparable quarterly earnings reports, but the core business has been ...

A new automation system from Abbott, designed to improve workflows in clinical lab settings, has been granted FDA approval. The system, GLP systems Track, uses a self-propelled carrier system that ...

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

A concussion test that Abbott Labs hopes someday could be used by sports team trainers and at urgent care clinics is now available for rapid use at the bedside, without having to send a sample to a ...

In a decisive move to fund one of its most significant strategic acquisitions in recent years, Abbott Laboratories has launched a massive $20 billion bond offering. The proceeds are earmarked to ...

Abbott Laboratories (NYSE: ABT) is a diversified health care company that gives investors a great deal of stability. Between testing, nutritional products, pharmaceuticals, and medical devices, the ...